Over the past decades, the knowledge regarding the pathophysiology of RA drove the discovery of several efficacious agents to cure patients unresponsive to DMARDs therapy, such as JAK/STAT inhibitors and novel biological drugs (i.e., anti-IL-17 and anti-IL-6 antibodies). Here, SOAT1 is linked to rheumatoid arthritis.